Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial
Authors:
- Bernard KikaireBKBernard Kikaire
- Ivan MambuleIMIvan Mambule
- Helen MusanaHMHelen Musana
- Godfrey MusoroGMGodfrey Musoro
- Charles F. GilksCGCharles F. Gilks
- Jonathan B. LevinJLJonathan B. Levin
- Anne Sarah WalkerAWAnne Sarah Walker
Open Access
- 13 November 2014
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (17) , 2579-2588
Abstract
We investigated the prevalence, incidence and predictors of new peripheral neuropathy episodes in previously untreated, symptomatic HIV-infected Ugandan/Zimbabwean adults initiating zidovudine-based antiretroviral therapy (ART).An open-label, multicentre, randomized trial.Peripheral neuropathy was self-reported at 12-weekly clinic visits. Cox regression models (excluding participants reporting preexisting peripheral neuropathy at ART initiation), considered sex; pre-ART WHO stage, age and CD4(+) cell count; CD4(+) cell count versus no CD4(+) cell count monitoring; and time-updated CD4(+) cell count, weight and use of stavudine, isoniazid and didanosine.Four hundred and twenty-one out of 3316(13%) patients reported preexisting peripheral neuropathy at ART initiation. Median (interquartile range, IQR) follow-up in 2895 participants without preexisting peripheral neuropathy was 4.9 (4.7-5.4) years. Three hundred and fifty-four (12%) took stavudine as first-line substitution and 518 (18%) took isoniazid during follow-up. Two hundred and ninety (11%) participants developed a new peripheral neuropathy episode, an incidence of 2.12 per 100 person-years. Eighteen (0.1%) had a grade 3/4 episode. Independent predictors of peripheral neuropathy were current stavudine use [adjusted hazard ratio (a)HR 4.16 (95% confidence interval, 95% CI 3.06-5.66], current isoniazid use [aHR 1.59 (95% CI 1.02-2.47)] and current didanosine use [aHR 1.60 (95% CI 1.19-2.14)]. Higher risks were independently associated with higher pre-ART weight [aHR (per+5 kg) 1.07 (95% CI 1.01-1.13)] and older age aHR (per 10 years older) 1.29 (95% CI 1.12-1.49), but there was no significant effect of sex (P = 0.13), pre-ART CD4(+) cell count (P = 0.91) or CD4(+) cell count monitoring (P = 0.73).Current stavudine, didanosine or isoniazid use continue to increase peripheral neuropathy risks, as does older age and weight at ART initiation; however, we found no evidence of increased risk in women in contrast to previous studies. The incidence of peripheral neuropathy may now be lower in ART programmes, as stavudine and didanosine are no longer recommended. All patients receiving isoniazid, either as part of antituberculosis (TB) chemotherapy or TB-preventive therapy, should receive pyridoxine as recommended in national guidelines.Keywords
This publication has 33 references indexed in Scilit:
- Effects of a Reduced Dose of Stavudine on the Incidence and Severity of Peripheral Neuropathy in HIV-Infected Adults in South AfricaAntiviral Therapy, 2012
- HIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional studyAIDS Research and Therapy, 2012
- Epidemiology of HIV-Related Neuropathy: A Systematic Literature ReviewAIDS Research and Human Retroviruses, 2012
- A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjectsBMC Infectious Diseases, 2011
- Sex Differences in the Incidence of Peripheral Neuropathy Among Kenyans Initiating Antiretroviral TherapyClinical Infectious Diseases, 2011
- A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settingsJournal of NeuroVirology, 2011
- Implementation of a Validated Peripheral Neuropathy Screening Tool in Patients Receiving Antiretroviral Therapy in Mombasa, KenyaThe American Journal of Tropical Medicine and Hygiene, 2010
- Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, RwandaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2010
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialThe Lancet, 2010
- Frequency and Characteristics of HIV-Associated Sensory Neuropathy Among HIV Patients in Bangkok, ThailandJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008